JAK Inhibitors in Immune Regulation and Treatment of Vitiligo DOI
Kewei Liu,

Linyi Zhou,

Meihui Shi

и другие.

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 80, С. 87 - 96

Опубликована: Ноя. 10, 2024

Язык: Английский

Epidemiology, genetics and management of vitiligo in the USA: an All of Us investigation DOI Creative Commons
Aditya K. Gupta, Vasiliki Economopoulos

Journal of Dermatological Treatment, Год журнала: 2025, Номер 36(1)

Опубликована: Фев. 26, 2025

Background Vitiligo is an autoimmune skin depigmentation disorder significantly impacting quality of life. This condition difficult to treat, with high relapse rates. Additionally, vitiligo associates other conditions, complicating patient management. Improving outcomes relies on understanding vitiligo's clinical landscape and genetic risk factors.

Язык: Английский

Процитировано

0
Recent trends in the treatment of vitiligo using novel drug delivery system DOI

Nandita Sahu,

Parag Jain,

Deepika Sahu

и другие.

International Journal of Pharmaceutics, Год журнала: 2024, Номер unknown, С. 125106 - 125106

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

2
JAK Inhibitors in Immune Regulation and Treatment of Vitiligo DOI
Kewei Liu,

Linyi Zhou,

Meihui Shi

и другие.

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 80, С. 87 - 96

Опубликована: Ноя. 10, 2024

Язык: Английский

Процитировано

1